As uncertainty looms over NIH funding, biotech leaders are stepping up with alternative financing solutions. Chris Gibson, co-founder and CEO of Recursion, along with serial biotech entrepreneur David Bearss, has launched the Altitude Lab Pre-seed Venture Fund, aimed at supporting early-stage biotech startups that typically rely on Small Business Innovation